Yizhou Dong
Biochemistry, Genetics and Molecular Biology · The Ohio State University
Publications
154
Citations
15,335
Est. group size
~16
Recurring co-author estimate
Active years
23
Publishing since 2004
Yizhou Dong's research focuses on developing chemical and molecular tools to deliver RNA-based therapies, including mRNA vaccines and gene-editing treatments, into cells and across biological barriers like the blood-brain barrier. Work in this profile spans designing lipid materials to carry RNA drugs, engineering RNA molecules for controllable gene expression, and applying these tools to vaccines, cancer immunotherapy, and viral infections. Note that a few entries in this record (on battery materials, electrocatalysis, and geopolitics) appear unrelated to this core focus and may reflect data mixing from other researchers with the same name.
Publication output has grown unevenly but substantially over the last decade, rising from single digits in 2017-2019 to notable peaks in 2020 and 2025, suggesting an overall increasing and active research pace in recent years.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- Engineering drug-responsive replication machinery for precise control of self-amplifying RNA
Nature Biomedical Engineering · 2026
- Cost-efficient closed-loop recovery and regeneration of LiFePO4 cathodes via a sodium persulfate-assisted route
Colloids and Surfaces A Physicochemical and Engineering Aspects · 2026
- RNA chemistry and therapeutics
Nature Reviews Drug Discovery · 2025
- Advances in the rational design of ionizable lipids for mRNA therapeutics
Materials Today · 2025
- Silver Induced In-Phase Electronic Interaction and Chloride Ion Repelling for Efficient Electrocatalytic Oxygen Evolution in Seawater Electrolysis
ACS Applied Energy Materials · 2025
- Chemical strategies for brain delivery of genomic therapy
Nature Reviews Chemistry · 2025
- Antibody Engineering for Receptor-Mediated Transcytosis Across the Blood–Brain Barrier
Bioconjugate Chemistry · 2025
- AI-powered design accelerates the development of mRNA therapeutics
Nature Chemical Biology · 2025
- Augmented humoral responses to HIV Env trimers delivered as transmembrane immunogens by self-replicating RNA
Molecular Therapy · 2025
- Engineering gene expression dynamics via self-amplifying RNA with drug-responsive non-structural proteins
bioRxiv (Cold Spring Harbor Laboratory) · 2025
- Targeted suppression of type 1 interferon signaling during RNA delivery enhances vaccine-elicited immunity
bioRxiv (Cold Spring Harbor Laboratory) · 2025
- Targeting ZNRF3 and RNF43 to Restore Regeneration and Reverse Metabolic Dysfunction-Associated Steatotic Liver Disease
bioRxiv (Cold Spring Harbor Laboratory) · 2025
- Single-dose cathepsin L CRISPR nanotherapy mitigates PASC-like lung damage in hamsters
Nano Research · 2025
- 609O CLDN18.2 targeted antibody-drug conjugate (ADC), SHR-A1904, in patients (pts) with gastric/gastroesophageal junction cancer (GC/GEJC): A phase I study
Annals of Oncology · 2024
- Integrative analysis identifies the atypical repressor E2F8 as a targetable transcriptional activator driving lethal prostate cancer
Oncogene · 2024
- UNC Libraries×7
- bioRxiv (Cold Spring Harbor Laboratory)×7
- Nature Biotechnology×4
- Nature Communications×4
- Bioconjugate Chemistry×4
- Huan Zhang
Biochemistry, Genetics and Molecular Biology · The Ohio State University
- Congcong Xu
Biochemistry, Genetics and Molecular Biology · The Ohio State University
- Dan Shu
Biochemistry, Genetics and Molecular Biology · The Ohio State University
- Fengmei Pi
Biochemistry, Genetics and Molecular Biology · The Ohio State University
- Sijin Guo
Biochemistry, Genetics and Molecular Biology · The Ohio State University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 19, 2026.
Claim or correct this profile